首页 › 基金 › Slate Path Capital LP › TVRD
Slate Path Capital LP 对 TVRD 的持仓历史
TVARDI THERAPEUTICS INC · 医疗保健
Slate Path Capital LP 在 Q3 2026 的 13F 申报中披露持有 TVRD(TVARDI THERAPEUTICS INC)704,118 股,市值约 US$880K,约占其申报组合的 0.01%,在其申报持仓中市值排名第 43 位。 Slate Path Capital LP 最近 6 个申报季度中有 6 个季度披露了 TVRD 持仓,最早可追溯至 Q2 2025。
最后更新: 2026-11-16 · 来源: SEC EDGAR Form 13F-HR
Slate Path Capital LP 对 TVRD 的持仓演变
Slate Path Capital LP 于 Q2 2025 首次披露 TVRD 持仓:704,118 股(约 US$16.4M)。 该持仓在 Q3 2025 达到峰值 704,118 股,市值约 US$27.4M。 在 6 次申报中,Slate Path Capital LP 的持股数量始终未变。 最近一期申报(Q3 2026)显示持股 704,118 股、市值约 US$880K。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q2 2025 | 704.12K | $16.43M | 新进 |
| Q3 2025 | 704.12K | $27.44M | 持有 |
| Q4 2025 | 704.12K | $3.03M | 持有 |
| Q1 2026 | 704.12K | $2.24M | 持有 |
| Q2 2026 | 704.12K | $1.34M | 持有 |
| Q3 2026 | 704.12K | $880.15K | 持有 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 TVRD 与 13F 数据
TVRD(TVARDI THERAPEUTICS INC)属于医疗保健行业。我们追踪的基金中还有 46 只申报持有 TVRD。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
更多关于 Slate Path Capital LP
常见问题
How long has Slate Path Capital LP held TVRD?
Slate Path Capital LP has disclosed TVRD holdings in 6 of the last 6 reported quarters, going back to Q2 2025.
What is Slate Path Capital LP's current position in TVRD?
As of Q3 2026, Slate Path Capital LP holds 704.12K shares of TVRD (TVARDI THERAPEUTICS INC), valued at $880.15K, representing 0.01% of its reported portfolio and ranking #43.
Has Slate Path Capital LP been buying or selling TVRD?
In the latest 13F filing (Q3 2026), Slate Path Capital LP held unchanged its position in TVRD. The position peaked in Q3 2025 at 704.12K shares.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.